A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET

Murali Chintagumpala, Tim Hassall, Shawna Palmer, David Ashley, Dana Wallace, Kimberly Kasow, Thomas E. Merchant, Matthew J. Krasin, Robert Dauser, Frederick Boop, Robert Krance, Shiao Woo, Robyn Cheuk, Ching Lau, Richard Gilbertson, Amar Gajjar

Research output: Contribution to journalArticlepeer-review

60 Scopus citations


We undertook this study to estimate the event-free survival (EFS) of patients with newly diagnosed supratento-rial primitive neuroectodermal tumor (SPNET) treated with risk-adapted craniospinal irradiation (CSI) with additional radiation to the primary tumor site and subsequent high-dose chemotherapy supported by stem cell rescue. Between 1996 and 2003, 16 patients with SPNET were enrolled. High-risk (HR) disease was differentiated from average-risk (AR) disease by the presence of residual tumor (M0 and tumor size > 1.5 cm2) or disseminated disease in the neuraxis (M1-M 3). Patients received risk-adapted CSI: those with AR disease received 23.4 Gy; those with HR disease, 36-39.6 Gy. The tumor bed received a total of 55.8 Gy. Subsequently, all patients received four cycles of high-dose cyclophosphamide, cisplatin, and vincristine with stem cell support. The median age at diagnosis was 7.9 years; eight patients were female. Seven patients had pineal PNET. Twelve patients are alive at a median follow-up of 5.4 years. The 5-year EFS and overall survival (OS) estimates for all patients were 68% ± 14% and 73% ± 13%. The 5-year EFS and OS estimates were 75% ± 17% and 88% ± 13%, respectively, for the eight patients with AR disease and 60% ± 19% and 58% ± 19%, respectively, for the eight with HR disease. No deaths were due to toxicity. High-dose cyclophosphamide- based chemotherapy with stem cell support after risk-adapted CSI results in excellent EFS estimates for patients with newly diagnosed AR SPNET. Further, this chemotherapy allows for a reduction in the dose of CSI used to treat AR SPNET without compromising EFS.

Original languageEnglish (US)
Pages (from-to)33-40
Number of pages8
Issue number1
StatePublished - Feb 2009


  • Autologous stem cell rescue
  • Craniospinal radiotherapy
  • Dose-intensive chemotherapy
  • Event-free survival
  • Risk-adapted therapy
  • Supratentorial PNET

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Clinical Neurology


Dive into the research topics of 'A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET'. Together they form a unique fingerprint.

Cite this